Capricor Therapeutics announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes. The Exclusive License Agreements with Cedars-Sinai ...

Capricor Therapeutics today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes. This patent, entitled "Exosomes and Micro...

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the ‘333 Patent), entitled “EXTRACORPOREAL REMOVAL ...

Regeneus, a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat ...

Company’s intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology Biocept, Inc. a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer ...

Aethlon Medical, Inc., announced today that the European Patent Office has granted European Patent Number 2591359, entitled “METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES.” Embodiments of the present invention relate to methods, compositions and kits for quantifying exosomes. In particular, methods, ...

Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging, Publication number WO2016201064 A1 Publication type Application Application number PCT/US2016/036629 Publication date Dec 15, 2016 Filing date Jun 9, 2016 Priority date Jun ...

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests ...

Creative Medical Technology Holdings (the “Company”) (OTCQB:CELZ) announced today filing of US patent application #62/400557 entitled “Treatment of Stroke by Amniotic Fluid Derived Stem Cell Conditioned Media and Products Derived Thereof.” The patent application covers the use of the Company’s ...

The present invention relates to a set of antibodies for detecting an exosome. More particularly, the present invention relates to a monoclonal antibody against a particular antigen (CD9, CD63, CD81) on an exosomal surface or an antibody fragment thereof, a ...